Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | KIFC1 | Q9BW19 | 15/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25450894 | 0.86 | RXRA (0.54) | RXRARXRBKIFC1KIF11 | |
| SCHEMBL25094360 | 0.85 | RXRA (0.57) | RXRARXRBKIFC1MCHR1 | |
| SCHEMBL24582834 | 0.75 | ALDH1A1 (0.49) | RXRARXRBKIFC1MCHR1 | |
| SCHEMBL25078587 | 0.73 | CYP1A2 (0.44) | KMT2A | |
| SCHEMBL12203377 | 0.72 | ALDH1A1 (0.55) | KMT2A | |
| SCHEMBL7936726 | 0.72 | HTT (0.54) | KMT2A | |
| SCHEMBL25094351 | 0.70 | RXRA (0.61) | RXRARXRBKMT2A | |
| SCHEMBL27659191 | 0.69 | KIF11 (0.76) | RXRARXRBKIF11 | |
| SCHEMBL14204058 | 0.69 | ALDH1A1 (0.38) | KMT2A | |
| SCHEMBL24061100 | 0.68 | HTT (0.57) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | RXRA 2426/4885RXRB 1594/4885KIFC1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.